BioSpace News Archive

sterna today announces its participation in the following key scientific and partnering conferences in the first half of 2018.

The sale includes Cardinal Health’s pharmaceutical and medical products distribution business in China.

PharmAbcine’s lead candidate TTAC-0001, an investigational therapy, is a highly selective and potent anti-VEGFR2 (KDR/flk-1) mAb in clinical development for rGBM indications.

Alnylam announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open.

Baxter International, Inc. today reported results for the fourth quarter and full-year ended December 31, 2017, and provided its financial guidance for 2018.

Getinge, a leading global provider of innovative medical technology, today announced the U.S. launch of its Maquet Moduevo ceiling supply unit product line.

Going forward, the existing Resonetics management team, led by CEO Tom Burns, will continue in their existing roles as a subsidiary of Regatta Medical.

The conference, which is being held February 5-9, 2018 in San Diego, CA, presents the latest information from basic science, translational research and clinical trials for lysosomal diseases.

The six posters evaluate the safety of Cladribine Tablets and its impact on the immune system via post hoc analyses of the CLARITY, CLARITY Extension, and ORACLE-MS trials, as well as the PREMIERE registry study.

icralyne Inc., a leading manufacturer of biomedical MicroElectroMechanical Systems (MEMS) and sensors announces the launch of the MicraFluidics™ technology - a line of standardized microfluidic process technologies to support high demand from the biomedical and life-sciences industry for rapid design and deployment of integrated microfluidic-based products.